PET Imaging of Phosphodiesterase-4B (PDE4B) in Alcohol Use Disorder

Last updated: March 25, 2025
Sponsor: National Institute of Mental Health (NIMH)
Overall Status: Active - Recruiting

Phase

1

Condition

Alcohol Use Disorder

Addictions

Alcohol Dependence

Treatment

18F-PF-06445974

Clinical Study ID

NCT06795581
10002210
002210-M
  • Ages 18-70
  • All Genders

Study Summary

Background:

People with alcohol use disorder (AUD) also often have bouts of depression called major depressive episodes (MDEs). People having MDEs have been found to have low levels of a protein called PDE4B in the brain. Researchers want to find out if people with AUD also have low levels of PDE4B. This research may help lead to better treatments for AUD.

Objective:

To find out (1) if PDE4B levels are lower in people who are withdrawing from AUD and (2) if their PDE4B levels go up after they abstain from alcohol for 3 to 4 weeks.

Eligibility:

Adults aged 18 to 70 years with AUD. They must be enrolled in protocol 14-AA-0181.

Design:

Participants enrolled in protocol 14-AA-0181 will stay in the clinic for 3 to 4 weeks for alcohol withdrawal. During this stay, they will have some added procedures for the current study.

Within the first week, participants will have a positron emission tomography (PET) scan of the brain. A needle will be used to guide a thin plastic tube (catheter) into a vein in one arm. An experimental substance called a radioactive tracer will be injected through the catheter. This tracer binds to PDE4B and makes it easier to see the protein in the brain. For the scan, participants will lie on a table that slides into a doughnut-shaped machine.

Participants will have a second PET scan toward the end of their stay in the clinic.

Participants may also have a magnetic resonance imaging (MRI) scan of the brain. They will lie on a bed that slides into a tube.

Eligibility Criteria

Inclusion

  • INCLUSION CRITERIA:

  1. Age 18-70 years

  2. Willingness to complete the study including MRI tests.

  3. Each participant must have a level of understanding sufficient to agree to allrequired tests and examinations and sign an informed consent document.

  4. Participants must have their radial artery pulse checked for the presence ofadequate ulnar collateral flow and the absence of any metal or foreign objectsin both wrists.

  5. Participants must agree to adhere to the lifestyle considerations.

  6. Enrolled in protocol 14-AA-0181

Exclusion

EXCLUSION CRITERIA:

Clinically significant abnormalities on laboratory testing beyond that expected in participants during alcohol withdrawal. This includes CBC and acute care panel (Na, K, Cl, CO2, creatinine, glucose, urea nitrogen).

  1. Clinically significant abnormalities on EKG.

  2. Participants who, in the investigator s judgment, pose a current serious suicidal orhomicidal risk.

  3. Participants with a breath alcohol level (BAL) past 0.08.

  4. Participants who have an unstable medical condition that, in the opinion of theinvestigators, makes participation unsafe (e.g., an active infection or untreatedmalignancy).

  5. Participants who have taken antidepressants or antipsychotic medications in the weekprior or during their hospital admission.

  6. HIV infection.

  7. Pregnancy.

  8. Have recent exposure to radiation related to research (e.g., PET from otherresearch) that, when combined with this study, would be above the allowable limits.

  9. Have an inability to lie flat and/or lie still on the camera bed for two hours,including claustrophobia, overweight greater than the maximum for the scanner, anduncontrollable behavioral symptoms, which will be screened by an interview with theparticipant during the screening visit.

  10. Are unable to have an MRI scan (e.g., because of pacemakers or other implantedelectrical devices, brain stimulators, dental implants, aneurysm clips (metal clipson the wall of a large artery), metallic prostheses (including metal pins and rods,heart valves, and cochlear implants), permanent eyeliner, implanted delivery pumps,shrapnel fragments, or metal fragments in the eye.

  11. Be NIMH staff or an NIH employee who is a subordinate/relative/co-worker of theinvestigators.

Study Design

Total Participants: 30
Treatment Group(s): 1
Primary Treatment: 18F-PF-06445974
Phase: 1
Study Start date:
March 20, 2025
Estimated Completion Date:
January 31, 2029

Study Description

Study Description:

AUD participants will be referred from protocol 14-AA-0181, which includes a four-week hospitalization at NIH for alcohol withdrawal. Using the PET radioligand [18F]PF974 to measure the density of PDE4B, AUD participants will be scanned twice: 1) within one week of admission, and 2) after 3-4 weeks of alcohol withdrawal.

Objectives:

Primary Objective #1: To determine whether PDE4B radioligand binding is decreased in AUD participants during acute withdrawal compared to healthy volunteers matched as a group for age and sex.

Primary Objective #2: To determine whether PDE4B radioligand binding increases in individuals on the second scan compared to the first.

Secondary Objective: No exploratory correlations are hypothesized for this novel imaging of PDE4B. However, we may later perform correlations with any of the clinical parameters or biological biomarkers obtained in the 14- AA-0181. Note that Dr. Diazgranados is an AI of this PET protocol, and Dr. Innis will become an AI of the parent protocol.

Endpoints:

Primary endpoint: For both objectives, the primary endpoint is PET measurement of PDE4B binding (VT) in all regions of the brain.

Connect with a study center

  • National Institutes of Health Clinical Center

    Bethesda, Maryland 20892
    United States

    Active - Recruiting

Not the study for you?

Let us help you find the best match. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.